Company Description
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases.
It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.
The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV).
In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-α receptor agonist targeting HBV and HDV.
The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014.
Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2005 |
| IPO Date | Dec 17, 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 73 |
| CEO | Jason Okazaki |
Contact Details
Address: Two Tower Place, 7th Floor South San Francisco, California 94080 United States | |
| Phone | 833 509 4583 |
| Website | assemblybio.com |
Stock Details
| Ticker Symbol | ASMB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001426800 |
| CUSIP Number | 045396108 |
| ISIN Number | US0453962070 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Nicole S. White Ph.D. | Chief Manufacturing Officer |
| Shannon Ryan | Senior Vice President of Investor Relations, Corporate Affairs and Alliance Management |
| Jennifer A. Troia MHROD, SHRM-SCP, SPHR | Chief Human Resources Officer |
| Thomas E. Rollins | Executive Officer |
| Amy Figueroa C.F.A. | Investor Relations Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 20, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 20, 2025 | 10-K | Annual Report |
| Mar 20, 2025 | 8-K | Current Report |
| Feb 20, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Jan 3, 2025 | 8-K | Current Report |
| Dec 26, 2024 | 8-K | Current Report |
| Dec 23, 2024 | SCHEDULE 13D/A | Filing |
| Dec 23, 2024 | SCHEDULE 13G/A | Filing |
| Dec 23, 2024 | SCHEDULE 13G | Filing |